Flora G, Nayak DrM. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des. 2019;25:4063.

Article  CAS  PubMed  Google Scholar 

Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol [Internet]. 2009;5:287–96. https://doi.org/10.1038/nrneph.2009.42.

Article  PubMed  Google Scholar 

Roehm B, Weiner DE. Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines. Curr Opin Nephrol Hypertens [Internet]. 2019;28. Available from: https://journals.lww.com/co-nephrolhypertens/fulltext/2019/05000/blood_pressure_targets_and_kidney_and.8.aspx.

Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation [Internet]. 2021;143:1157–72. https://doi.org/10.1161/CIRCULATIONAHA.120.050686. This overview article summarizes the current understanding and clinical consequences of cardiovascular disease in CKD.

Article  CAS  PubMed  Google Scholar 

Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation [Internet]. 2020;142:e265-86. https://doi.org/10.1161/CIR.0000000000000920.

Article  CAS  PubMed  Google Scholar 

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med [Internet]. 2004;351:1296–305. https://doi.org/10.1056/NEJMoa041031.

Article  CAS  PubMed  Google Scholar 

Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med [Internet]. 2001;134:629–36. Available from: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-134-8-200104170-00007.

Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med [Internet]. 2004;351:1285–95. https://doi.org/10.1056/NEJMoa041365.

Article  CAS  PubMed  Google Scholar 

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One [Internet]. 2016;11:e0158765-. https://doi.org/10.1371/journal.pone.0158765.

Article  CAS  PubMed  Google Scholar 

Prevalence of CKD among U.S. adults [Internet]. [cited 2023 Sep 29]. Available from: https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q9&topic=1#refreshPosition. Accesed 29 Sep 2023.

Kim K, Oh H, Choi H, Lee H, Ryu D-R. Impact of chronic kidney disease on mortality: a nationwide cohort study. Kidney Res Clin Pract. 2019;38:382.

Article  PubMed  PubMed Central  Google Scholar 

Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 Clinical Practice Guideline. Ann Intern Med [Internet]. 2013;158:825–30. Available from: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-158-11-201306040-00007.

Neild GH. Primary renal disease in young adults with renal failure. Nephrol Dial Transplant [Internet]. 2010;25:1025–32. https://doi.org/10.1093/ndt/gfp653.

Article  PubMed  Google Scholar 

Durham A, Speer M, Scatena M, Giachelli C, Shanahan C. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 2018;114:590–600.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tuka V, Slavikova M, Kasalova Z, Malik J. Factors associated with impaired arterial adaptation to chronically high wall shear rate in the feeding artery of PTFE grafts. Am J Nephrol [Internet]. 2008;28:847–52. https://doi.org/10.1159/000137685.

Article  PubMed  Google Scholar 

Park S, Lee SH, Shin D, Hong D, Joh HS, Choi KH, et al. Prognostic impact of coronary flow reserve in patients with CKD. Kidney Int Rep [Internet]. 2023;8:64–74. https://doi.org/10.1016/j.ekir.2022.10.003.

Article  PubMed  Google Scholar 

Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Min Res [Internet]. 2005;20:1912–20. https://doi.org/10.1359/JBMR.050711.

Article  Google Scholar 

Townsend RR, Anderson AH, Chirinos JA, Feldman HI, Grunwald JE, Nessel L, et al. Association of pulse wave velocity with chronic kidney disease progression and mortality. Hypertension [Internet]. 2018;71:1101–7. https://doi.org/10.1161/HYPERTENSIONAHA.117.10648.

Article  CAS  PubMed  Google Scholar 

London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial [Internet]. 2003;16:85–94. Available from: http://europepmc.org/abstract/MED/12641870.

Malík J, Kudlicka J, Tuka V, Chytilova E, Adamec J, Rocinova K, et al. Common carotid wall shear stress and carotid atherosclerosis in end-stage renal disease patients. Physiol Res [Internet]. 2012;61(4):355–61. Available from: https://api.semanticscholar.org/CorpusID:23256505.

Malik J, Novakova L, Valerianova A, Chytilova E, Lejsek V, Buryskova Salajova K, et al. Wall shear stress alteration: a local risk factor of atherosclerosis. Curr Atheroscler Rep [Internet]. 2022;24:143–51. https://doi.org/10.1007/s11883-022-00993-0.

Article  Google Scholar 

Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J [Internet]. 2021;42:2170–85. https://doi.org/10.1093/eurheartj/ehaa1050. This overview article highlights the current knowledge about lipoproteins in CKD.

Article  CAS  PubMed  Google Scholar 

Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem [Internet]. 2010;56:977–86. https://doi.org/10.1373/clinchem.2009.142810.

Article  CAS  PubMed  Google Scholar 

Kastarinen H, Hörkkö S, Kauma H, Karjalainen A, Savolainen MJ, Kesäniemi YA. Low-density lipoprotein clearance in patients with chronic renal failure. Nephrol Dial Transplant [Internet]. 2009;24:2131–5. https://doi.org/10.1093/ndt/gfp026.

Article  CAS  PubMed  Google Scholar 

Reis A, Rudnitskaya A, Chariyavilaskul P, Dhaun N, Melville V, Goddard J, et al. Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease [S]. J Lipid Res [Internet]. 2015;56:413–22. https://doi.org/10.1194/jlr.M055624.

Article  CAS  PubMed  Google Scholar 

Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol [Internet]. 2012;60:2372–9. Available from: https://www.sciencedirect.com/science/article/pii/S0735109712046517.

Wang K, Zelnick LR, Hoofnagle AN, Vaisar T, Henderson CM, Imrey PB, et al. Alteration of HDL protein composition with hemodialysis initiation. Clinical Journal of the American Society of Nephrology [Internet]. 2018;13. Available from: https://journals.lww.com/cjasn/fulltext/2018/08000/alteration_of_hdl_protein_composition_with.15.aspx.

Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity [Internet]. 2013;38:754–68. Available from: https://www.sciencedirect.com/science/article/pii/S1074761313000885.

Mayer O Jr, Seidlerová J, Wohlfahrt P, Filipovský J, Vaněk J, Cífková R, et al. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. J Hum Hypertens [Internet]. 2016;30:418–23. https://doi.org/10.1038/jhh.2015.55.

Article  CAS  PubMed  Google Scholar 

Wanner C, Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens [Internet]. 2001;10. Available from: https://journals.lww.com/co-nephrolhypertens/fulltext/2001/03000/dyslipidemia_and_renal_disease__pathogenesis_and.7.aspx.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews [Internet]. 2014. https://doi.org/10.1002/14651858.CD007784.pub2.

Rosenstein K, Tannock LR. Dyslipidemia in chronic kidney disease. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc; 2000.

Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study. J Am Coll Cardiol [Internet]. 2008;51:1448–54. Available from: https://www.sciencedirect.com/science/article/pii/S0735109708003549.

Wanner C, Krane V, März W, Olschewski M, Mann J, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

Article  CAS  PubMed  Google Scholar 

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med [Internet]. 2009;360:1395–407. https://doi.org/10.1056/NEJMoa0810177.

Article  CAS  PubMed  Google Scholar 

März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology [Internet]. 2011;6. Available from: https://journals.lww.com/cjasn/fulltext/2011/06000/atorvastatin_and_low_density_lipoprotein.14.aspx.

Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology [Internet]. 2011;22. Available from: https://journals.lww.com/jasn/fulltext/2011/07000/rosuvastatin_in_diabetic_hemodialysis_patients.21.aspx.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet [Internet]. 2011;377:2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3.

Article  CAS  Google Scholar 

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev [Internet]. 2013. https://doi.org/10.1002/14651858.CD004289.pub5.

Vaziri ND, Norris KC. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations. Blood Purif [Internet]. 2013;35:31–6. https://doi.org/10.1159/000345176.

Article  CAS  PubMed  Google Scholar 

Wanner C, Tonelli M, Members the KDIGOLGDWG. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int [Internet]. 2014;85:1303–9. https://doi.org/10.1038/ki.2014.31.

Article  CAS  PubMed  Google Scholar 

Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;212534. https://doi.org/10.7573/dic.212534.

Morita T, Morimoto S, Nakano C, Kubo R, Okuno Y, Seo M, et al. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014;53:307–14.

Article  PubMed  Google Scholar 

Stanifer J, Charytan D, White J, Lokhnygina Y, Cannon C, Roe M, et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. J Am Soc Nephrol. 2017;28:ASN.2016090957.

Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep [Internet]. 2009;11:338–42. https://doi.org/10.1007/s11883-009-0051-5.

Article  CAS  PubMed  Google Scholar 

Jun M, Zhu B, Tonelli M, Jardine M, Patel A, Neal B, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:2061.

Article  CAS